Rats received pentobarbitone (60, 48 and 36mg/kg i.p.) or ketamine/medetomidine (75/100,60/80 and 45/60mg/llg/kg i.p.l alone, or one hour following buprenorphine (0.5 mg/kg s.c.). Animals were anaesthetized once per week for 6 weeks with one of three anaesthetic doses according to a randomized block design. In the pentobarbitone group, animals which received buprenorphine had longer sleep times (236 ± 22 d. 204 ± 21 min) and longer durations of surgical anaesthesia (83± 14 d. 27 ± 8 min) (P<O.OI), these effects being potentiated with increasing anaesthetic doses (P<O.OlI. A greater degree of respiratory depression was found in animals that received buprenorphine (P<0.011 although this was judged clinically acceptable in all cases. Unexpectedly high mortality and a high incidence of anaesthetic complications (nine of 16 animals) in the ketamine/medetomidine group made statistical analysis of these data impossible. We conclude that for pentobarbitone, preanaesthetic administration of buprenorphine reduces the dose of anaesthetic required to produce surgical anaesthesia, in addition to the presumed benefits of pre-emptive analgesia. In view of the high mortality encountered, we advise caution when considering preanaesthetic use of opioids in combination with ketamine/medetomidine in rats.
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A number of studies in man have suggested that preoperative administration of analgesics is a more effective means of providing post-surgical analgesia than administration postopera"tively, and laboratory investigations have demonstrated the mechanisms that may be involved in these effects (Woolfe & Wall 1986) . Limited data in animals sug-Correspondence to: /. V. Roughan gest that this may significantly improve analgesic efficacy (Lascelles et al. 1995) , and preoperative drug administration may be of benefit to both veterinary clinical practice and laboratory animals. Aside from the provision of postoperative pain relief, some analgesic agents are likely to potentiate the effects of anaesthetics, so "enabling the dose of anaesthetic required for surgical anaesthesia to be reduced. For example, many opioids have been shown to reduce the concentration of volatile anaesthetic necessary to produce surgical anaesthesia (Kay 1980 , Hecker 1983 , Stanley 1983 , Kissin 1984 .
Opioids have also been shown to reduce the dose of injectable anaesthetics required in animals and man (Michalot et a1. 1980 , DeWildt 1983 , Hilton 1986 , Flecknell et aJ. 1990 ). However, it appears that no studies have been conducted to determine the interactions of opioids with the commonly used injectable anaesthetics in laboratory rodents. The potentiation of anaesthetic effects is likely to be of considerably greater practical significance in these species than in "larger animals. In larger species, injectable anaesthetics are usually administered by the intravenous route, so enabling the required dose to be adjusted easily, depending upon the animal's response. In small rodents, injectable anaesthetics are usually administered as a single i.p. s.c. or i.m. injection, allowing no opportunity to adjust the dose during induction. If pre-anaesthetic administration of opioids potentiated the effects of anaesthetic agents, this could lead to relative overdosage and increased mortality. Other concerns might be that pre-anaesthetic administration of an opioid could cause additional respiratory depression, or could result in prolonged recovery times. This study was undertaken to determine whether clinically apparent interactions could be detected between buprenorphine, an opioid analgesic, and two anaesthetic regimens commonly used in laboratory rodents: pentobarbitone and the combination of ketamine with medetomidine.
Materials and methods

Animals
Outbred Wistar rats, weighing between 120 and ISOg were obtained from the Specific Pathogen Free Unit of the Comparative Biology Centre. Animals were group-housed in single-sex groups in solid floored caging (RCl, NKP Ltd, 56 em x 38 em, height 18em). Sawdust ('Gold Chip' BS and S Ltd, Edinburgh, UK) was used as bedding. Stocking densities were within UK specified guidelines (Home :Office Animals (Scientific Procedures) Act 1986, 19891.Room temperature was controlled at 20±2°C. A 9h: ISh light-dark cycle was maintained, (lights on at 08:00 h and off at 17:00 h). Animals received a commercial pelleted diet (R and M No.1, SDS Ltd, Essex, UK) and water ad libitum.
Anaesthetic methods
Pilot study
Initially, a pilot study was conducted which aimed to establish appropriate dose rates. This used 12 rats (six male, six female). All animals received a single dose of buprenorphine (Temgesic, Reckitt and Coleman) (0.05mg/kg s.c.), this dose having been shown to have a significant analgesic effect following laparotomy in rats (Liles & Flecknell 1994) . Animals were then divided into groups which received either pentobarbitone (Sagatal, Rhone Merieux) or ketamine (Vetalar, Parke-Davis) and medetomidine (Domitor, Pfizer) one hour following buprenorphine administration. Within each group, two animals were given one of three drug dosages, these having been shown from previous experience to provide, respectively, a long, medium and short duration of anaesthesia when administered alone. Drug dosages were, for pentobarbitone 60, 48 and 36 mg/kg and for ketamine/medetomidine 75/100, 60/80 and 45/60 mg/J.lgper kg. All anaesthetics were administered by the i.p. route.
Main study
Two weeks following the completion of the pilot study, the same 12 animals together with an additional 12 rats (six male, six female) were used for the main study. The animals were divided into groups that received either pentobarbitone (group 1) or ketamine/medetomidine (group 2). Within each group, animals were further sub-divided into equal-sized groups of males and females that either received saline (0.2ml/100g) or buprenorphine (0.05mg/kg s.c.) one hour prior to induction. All drugs were diluted before use with sterile water for injection, to provide a suitable volume for accurate dosing (0.2-0.4ml/animal). To determine whether the characteristics of each anaesthetic com-bination were affected by the time of day that administration took place, anaesthetics were given either in the morning (10:00 h) or the afternoon (14:00 h). These times were chosen to comply with normal laboratory working practice. A randomized block design was employed to determine the type of pre-treatment that animals were given, the dose of anaesthetic subsequently administered and the time the procedure took place on each anaesthesia day. To determine the effect of repeated anaesthesia, a repeated measures design was employed such that each animal received six anaesthetics, with an interval of at least 5 days between each. As the respective plasma elimination half-lives of buprenorphine, ketamine and medetomidine administered to rats have been determined to be, respectively 2.8 (Ohtani et al. 1994 ), one (White et al. 1976 ) and 1.6 h (Salonen 1989), this interval was considered sufficient to assume that no drug 'carry-over' effect would occur. This design was used to maximize the information obtained from the study while at the same time minimizing the number of animals used. In this and the pilot study, after the onset of anaesthesia (judged by loss of the righting reflex) the rats were placed on bedding IVetBed, Alfred Cox), on a heating pad (Harvard Instruments) and ophthalmic ointment (Chloromycetin, Parke-Davis) was applied to the eyes to prevent corneal desiccation or abrasions.
During anaesthesia, assessments were made using six measurement criteria following each 15 min period of anaesthesia. These were:
(1) Respiratory rate (number of breaths in a 15 s periodli (2) Pedal withdrawal response (response to a pinch to the hind-foot metacarpal region), scored from 1 (no response) to 3 (stron'g withdrawal); (3) Total sleep time (duration from loss of righting reflex until ability to perform three consecutive righting responses when placed in dorsal recumbency); (4) Latency to first movementj (5) Total duration of surgical anaesthesia (the duration over which a pedal withdrawal score of one was maintained);
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The righting reflex was considered absent when the rat made no attempt to perform it when placed in dorsal recumbency. During the pilot study, it became apparent that the latency of restoration of the righting reflex was extremely variable, and that a better assessment of the duration of unconsciousness could be obtained by also recording the time to the first spontaneous movement (usually limb movements and partial righting).
All assessments were carried out by an observer who was unaware of the treatment each rat had received. After the animals had regained their ability to perform three consecutive righting reflexes, they were placed in an incubator maintained at 28°C until normal ambulatory behaviour resumed. They were then returned to their cages in the animal room.
Emergency treatment
If apnoea occurred (no respiratory movements for 60 s), or sustained marked respiratory depression occurred «4 breaths/min for >2min), then ventilation was assisted by manual compression of the thorax, and atipamezole (Antesedan, Pfizer pic.) (1 mg/kg) administered intravenously via the lateral tail vein (if the animal had received medetomidinel. Oxygen was provided by a face mask, and if severe dyspnoea occurred, or apnoea persisted for more than 4 min, then the animal was intubated using a 14 gauge catheter and gentle intermittent positivepressure ventilation was applied.
Data analysis
Although a randomized block arrangement for treatment administration was employed, this meant that not all treatment combinations were administered on each consecutive anaesthesia day (hence Table 2 shows missing data). The data were therefore analysed using the REML (restricted maximum likelihood) procedure in Genstat 5.0 to perform unbalanced analyses of variance.
In designing this study our primary aim was to determine the consequences of pretreatment with buprenorphine on the overall characteristics of anaesthesia, thus the data for each treatment combination were pooled for all individual time samples each day and over all anaesthesia days. Unbalanced analyses of variance then examined differences in response characteristics between each combination of pre-treatment type and subsequent dose of pentobarbitone, according to the above listed criteria. Although a maximum of 43 individual samples were taken, average pedal withdrawal scores and respiratory rates were calculated using only the first 14 samples. This was because missing data occurred as a result of large between-treatment variations in the durations of depression of pedal withdrawal reflexes and respiratory rates.
In addition to treatment associated differences in the parameters listed above, we wished to examine any influence of repeating anaesthesia on six occasions, and also whether the characteristics of anaesthesia were influenced by the time of day that each combination was administered (morning or afternoon). For these analyses, total sleep time was examined as a variable summarizing the effects of each anaesthetic treatment. This produced some unexpected results in relation to the effects of repeated anaesthesia, especially in the case of animals in group 2 (ketaminejmedetomidine). Due to anaesthetic-related mortality, four rats were added to this groupi however, as described below, the withdrawal of several additional cases prevented formal statistical analysis of the data obtained from the ketaminej medetomidine group.
Results
Establishment of dose rates
The effects of the low, medium and high anaesthetic doses chosen (see above) ranged from light anaesthesia (low doseL with animals barely losing their righting reflex, to deep surgical anaesthesia (high dosel characterized by complete loss of the pedal withdrawal reflex. Animals that received buprenorphine together with the lower doses of anaesthetic appeared to be more deeply anaesthetized than animals which did not receive buprenorphine, but because of the small numbers involved, no formal statistical analysis was undertaken. As all animals recovered uneventfully, the doses chosen at this stage were considered safe and were used in the main study.
Main study
Pentobarbitone
Over all doses of pentobarbitone used, animals that received buprenorphine prior to anaesthesia with pentobarbitone experienced a longer duration of surgical anaesthesia (mean±SEM) (83±I4 d. 27±8min) (P<O.OILlonger latencies to first movement (197±21 d. 128± 15min) (P<0.0l1 and longer total sleep times (236± 22 d. 204±21 min) (P=0.009) than rats which received only pentobarbitone. In each case these effects became more pronounced with increasing pentobarbitone dose (P<0.04i P<O.OOli P<O.OOI for each respective measure) (Fig 1 and Table 1 ). The overall average pedal withdrawal score (samples 1 to 14) for rats receiving each anaesthetic combination are shown in Fig 2. Animals which received buprenorphine showed lower pedal withdrawal scores (were less responsive) (p<O.OOn and these reductions were again enhanced by increasing the dose of pentobarbitone given (P = 0.002) (Fig 2) . Respiratory depression occurred in all animals during anaesthesia, however this effect was greater in animals that received buprenorphine (P<O.009)ITable 1). Also, as shown in Table I , recovery times increased with increasing dose of anaesthetic, and were again significantly greater in animals that received buprenorphine (P=0.008). Over all anaesthesia days, and irrespective of whether animals received buprenorphine, or the pentobarbitone dose used, respiratory depression was greater in females than in males (P = 0.001). The effect of repeating anaes- to first movement and total sleep time for animals which received buprenorphine or saline prior to one of three doses of pentobarbitone (60, 48 and 36 mg/kg). Data were averaged over all anaesthesia days. Note that in comparison with animals that received saline, those pre-medicated with buprenorphine were more deeply anaesthetized at equivalent doses of pentobarbitone (saline group, n = 12, buprenorphine group, n = 12) thesia was a significant increase in total sleep time, the effect again being co-dependant on the dose of pentobarbitone (P<O.OOl) (Table  21. Inspection of Table 2 , however, shows that this relationship was not as consistent as the high level of significance would suggest. The time of day (morning or afternoon I that anaesthesia was induced had no significant effect on the variables studied (P>O.OS). Table 3 indicates the numbers of occasions on which animals attained surgical planes of Ketamine / medetomidine Rats were anaesthetized without incident on two occasions. During the third anaesthetic, one animal died (buprenorphine/low-dose ketamine/medetomidine), and two rats in the same dose group became cyanotic and received atipamezole. Three animals were added to the ketamine/medetomidine group to replace these animals. Two of these animals died, one after being anaesthetized with low-dose ketamine/medetomidine and buprenorphine, the other after high-dose anaesthetic and no buprenorphine. The other rat received low-dose ketamine/medetomidine and no buprenorphine, and required reversal with atipamezole. One of the original group died after receiving high-dose ketamine/ medetomidine and buprenorphine, and another which received low-dose anaesthetic and no buprenorphine requil'ed reversal with atipamezole. During the fifth anaesthetic session, five animals (two high-dose with buprenorphine, two high-dose with no buprenorphine, and one low-dose with buprenorphinel required reversal with atipamezole. One animal (low-dose, no buprenorphine) died.
Animals which died despite attempts at resuscitation developed dyspnoea associated with clinical signs of acute pulmonary oedema, the presence of which was confirmed on postmortem examination.
Discussion
Ketamine has been widely used for anaesthesia of laboratory rats, most frequently in combination with xylazine. Ketamine combined with medetomidine, a more selective alpharadrenoreceptor agonist, has become established as a popular anaesthetic regimen, primarily because of the availability of atipamezole, a highly specific alpha2-adrenoreceptor antagonist lFleckneIl19961. Since ketamine has minimal anaesthetic effects when used alone in rodents, the reversal of medetomidine results in a rapid, marked reduction in anaesthetic depth and the shortening of recovery times. Pentobarbitone has long been used as an anaesthetic for rodents, despite its poor analgesic qualities and narrow safety margin lField et ai. 1993). The dose rates of the anaesthetics selected for study' were intended to provide light to medium planes of anaesthesia in the strain of rat used, and this was confirmed in the pilot study.
Noxious stimuli have been shown to cause C-fibre induced excitability changes in the spinal cord. These changes result in a lowering of the pain threshold. If morphine is administered before noxious stimulation, the dose required to block these changes is an order of magnitude lower than if morphine is given after the changes have occurred IWoolfe & Wall 1986). The prevention of sensitization by surgical stimuli is the basis for the clinical application of pre-emptive analgesia, and although opinion is currently divided concerning the practical relevance of this technique in man (McQuay et al. 1988 , Dahl et al. 1992 , 1993 , Ejlerson et al. 1992 , it has been strongly recommended in veterinary and laboratory animal anaesthetic practice (Lascelles et al. 1995 (Lascelles et al. , 1997 . If preoperative administration of analgesics provides more effective pain relief than postoperative administration, then it is clearly desirable to adopt this regimen. However, it is important to establish 'whether clinically significant interactions occur between the analgesic agent used and the anaesthetic regimen. Of particular concern is the possibility of increased respiratory depression, and of prolongation of recovery times. Conversely, the use of preoperative analgesics may enable a reduction of the required dose of other anaesthetic agents, in effect contributing an analgesic component to a balanced anaesthetic regimen.
In the present study, preoperative administration of the partial 11 opioid agonist, Laboratory Animals (1999) 33 Roughan, Burzaco Ojeda & Flecknell buprenorphlne, had an additive effect on pentobarbitone anaesthesia. Data indicated that recommended doses of pentobarbitone can be reduced by at least 20% when buprenorphine is used as a pre-anaesthetic medication. As a consequence of anaesthetic complications and the mortality in animals which received ketamine/medetomidine, formal statistical data analysis could not be undertaken, but inspection of the data suggested that an additive effect of buprenorphine, similar to that seen with pentobarbitone occurred. The administration of buprenorphine significantly improved the reliability of pentobarbitone anaesthesia. Over all occasions when pentobarbitone was administered alone, animals attained a surgical plane of anaesthesia (as judged by the complete loss of the pedal withdrawal response) on 14 occasions, in comparison to 26 in those that received buprenorphine ( Table 3 ). The administration of buprenorphine had a small but significant effect on respiratory rate which was not judged to be of clinical significance. The most reliable means of measuring the effects on respiratory function would have been by arterial blood gas analysis, but this would have required invasive surgery, and was not considered justifiable in these initial investigations. Attempts to measure oxygen saturation using pulse oximetry were not successful, which in the case of animals anaesthetized with medetomidine, was probably due to the marked peripheral vasoconstriction produced (Golden et al. 1998) . Although major effects were not detected, it should be noted that at the dose rate used, buprenorphine has only very minor respiratory depressant effects when administered alone to normal animals, and care should be taken if full 11 agonists, such as morphine, are used.
Although buprenorphine prolonged recovery times, inspection of Fig 1 shows that in the absence of buprenorphine, a pentobarbitone dose of 60 mg/kg is effective in producing approximately 45 min of surgical anaesthesia, whereas if buprenorphine is given, a lower dose of 36 mg/kg is sufficient to provide at least one hour of surgical anaesthesia in an identical proportion of animals/number of occasions 19/12llTable 3). Comparing these equi-anaesthetic groups also indicates that the duration of surgical anaesthesia and the times of latency to first movement are comparable (Fig 1 and Table   1 ).
A serious and unexpected effect that emerged was a high incidence of anaesthetic deaths and respiratory arrests in rats given ketamine/medetomidine. This did not occur until mid-way through the study, and initially appeared to be associated with repeated anaesthesia, however, at the next anaesthetic session, three rats being anaesthetized for the first time also developed anaesthetic complications. The rats died of respiratory failure, with animals developing acute pulmonary oedema.
Female rats appeared more susceptible to the effects of the agents used. Females showed a small but insignificantly greater total sleep time and latency to first movement, but a significantly greater degree of respiratory depression. Although the latter does not necessarily imply deeper anaesthesia, we suggest that this be taken into consideration when using this regimen. This sex variation is opposite to that reported with pentobarbitone in mice (Lovell 19861. All dose rates were calculated on a mg/kg basis, and allometric scaling was not used (Morris 1995). Had dose rates based on a mg/kg O . 75 been employed, this would have led to increased dose rates being used in the smaller female rats, and this would probably have further increased the differences between the two sexes.
In conclusion, the administration of buprenorphine had a clear anaesthetic-sparing effect, which would allow a subsequently administered dose of pentobarbitone to be reduced by approximately 20%; although when adopting this regimen, dose titration studies should be undertaken in the particular strain of rat which is to be used. In our experience, ketamine used in combination with medetomidine provides a safe and effective means of anaesthetizing rats. The unexpected mortality seen in the ketamine/ medetomidine group in the present study suggests that caution should be exercised when these drugs are administered either in combination with pre-anaesthetic opioid analgesics such as buprenorphine, or within a regimen of repeated anaesthesia. The latter will be the focus of further studies aimed at establishing safety limits for ketamine/ medetomidine administered repeatedly by either subcutaneous, intramuscular or intraperitoneal routes. Liles JH, Flecknell PA (1994) 
